Posted on

Clinical Insight: Engaging PWID in HCV Care

Volume 6, Issue 4.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

In the Clinic: Identifying & Managing HCV Complications

Volume 6, Issue 2.

In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

START HCV: Part 2

Hep C (HCV) treatment is easier and more effective, than ever. Cure is almost always expected when treated—even current drug users—so learn how you can cure HCV and help prevent re-infection, liver damage, cancer and death. Take the post-test to claim your credit.

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS